Share Name Share Symbol Market Type Share ISIN Share Description
Futura Medical Plc LSE:FUM London Ordinary Share GB0033278473 ORD 0.2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.50 1.64% 31.00 30.50 31.50 31.00 30.50 30.75 735,552 16:21:47
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -7.2 -4.5 - 63

Futura Medical Share Discussion Threads

Showing 16701 to 16723 of 17925 messages
Chat Pages: Latest  669  668  667  666  665  664  663  662  661  660  659  658  Older
DateSubjectAuthorDiscuss
16/4/2019
18:36
Mira - LO have been reducing for ages - check the holdings RNSs - and it looks as though they want out. I doubt the random magazine article means much in the grand scheme of things. However, given LO's current holding, there's the prospect of a lot more pain still to come for other holders. Caveat emptor.
supernumerary
16/4/2019
17:20
After hours rns?
akmal101
15/4/2019
11:43
hTTps://www.investorschronicle.co.uk/comment/2019/04/15/futura-s-blue-sky-opportunity/
cf456
15/4/2019
11:43
This is just waiting to be snapped up by a larger fish.
j777j
15/4/2019
11:24
Tipped by ST in the IC
mirabeau
12/4/2019
13:19
Yes very impressive.
j777j
12/4/2019
08:15
I have just listened to the Investor presentation.I have to say that you cannot help but be impressed by Ken James.He is enthusiastic about the product,and about the progress of the studies ,but more importantly ,he explains everything with great clarity.Despite all the past wrong turns,I strongly feel if Med is only half as effective as FUM hope it is still going to be a massive driver of share holder value.If only Lombard were not sitting on millions of shares that will feed the market I'm sure we would see real progress in the share price.Keep the faith.
martinelwick
12/4/2019
07:50
Why the rise?
herb clark
12/4/2019
07:46
Bouncing back strongly!
andyj
11/4/2019
15:10
Interesting webcast. Recruitment going well. Headline data expected by year end, maybe sooner. Let's hope that the rules are being followed properly at each centre, if that's ok it's looking good for MED I think.
rrr
11/4/2019
13:57
Puntastic post. Deserved more people pushing their thumbs up....
groogis
11/4/2019
13:40
htTPS://webcasting.brrmedia.co.uk/broadcast/5ca77b48eb566331974d52e8
j777j
11/4/2019
13:37
Good webcast.I like Ken James he is more able to speak in words the masses can understand.Clearly the co know what they have been offered by potential partners,yet believe they can get significantly more by hanging on until year end.We know Singer has pencilled in $30 million in upfront and milestone payments from Europe and $60 million from the USA.Phase 3 is all systems go with 500 recruits already expected to have been enrolled by end of this week.Not long to wait.
j777j
11/4/2019
07:44
Barder is out of his depth, there is some fantastic science here but it needs someone with vision/ contacts to exploit it. He has been here too long!
slicethepie
10/4/2019
22:42
what happened with the Blue Diamond condoms? They were in sale in Holland and Belgium now they've completely disappeared. The feedback on these from what I've seen was pretty positive from people that bought them then nothing. Was it Durex pulling out that finished this product range off? All I can think is Durex pulled out to develop their own product but I cannot see one out there anything like this they've focused on different gel types to delay the inevitable not the make it rock hard.
creditcrunchies
10/4/2019
17:05
mtb - I find it pretty unbelievable that nobody's prepared to take this to market. Seems like a perfect product for some upstart newcomer to take on. I wonder what terms Barder's asking for? He really is a lazy sod, isn't he?
supernumerary
10/4/2019
15:57
tiananmen that is exactly what FUM said about CSD500 the 'viagra' condom and look what happened to that - nothing, except revenue down from £360K in 2017 to ZERO in 2018 ! - at least in 2017 it covered Barders 1/4million+ remuneration ! From todays report :- CSD500 - condom containing the erectogenic Zanifil(R) gel In September 2018, Futura received approval for a two-year shelf life for CSD500 for its European contract condom manufacturer. This milestone provides the company with an opportunity to focus its R&D resource fully on the far greater potential of its leading asset, MED2005. As an innovative specialist R&D company, Futura does not have the marketing or regulatory medical device resource available to support the day-to-day requirements in a growing compliance-driven market and is in discussions with potential partners to assume these obligations. Futura expects to still benefit from the Intellectual Property of CSD500 through potential royalties, but the immediate potential for substantial royalties is low in the absence of a large global brand 'carrier' to take the product forward as previously advised. The Company will continue to explore national, multi-territory and regional agreements where the opportunities arise. The Company is expected to benefit from annual cost savings of approximately GBP400k in the event that it no longer maintains regulatory clearance itself for CSD500 as a medical device. - don't hold your breath !
mikethebike4
10/4/2019
14:38
We were not expecting anything significant from today's announcement and that is what we got. We still have to wait until the Phase III results are finished until it gets approval, nothing has changed, the early signs is that this drug is going to make a substantial impact on the market.
tiananmen
10/4/2019
12:57
That is for the USAFirst one is for Europe and we are half way stage.15% royalties on $1.4 billion peak sales is $210,000,000 a year.That is 5 times current market cap annually.All to play for.
j777j
10/4/2019
12:30
They also said... "Planning for a SECOND, CONFIRMATORY Phase 3 study for MED2005 has been UNDERTAKEN.. ... THIS STUDY is expected to be informed by the FIRST Phase 3 and therefore START AFTER END of the FIRST PHASE 3 STUDY... The way I see it - 'POTENTIAL' and 'EXECUTION' are two totally different beasts. Only time will tell. ATB
5oletrader
10/4/2019
11:26
Meanwhile back in the real world,it is all systems go for a product that could generate 15% royalties on peak sales of $1.4 billion pa."Futura medical confirmed it will deliver the results from its phase III trial for a fast-acting gel for erectile dysfunction (ED) by the end of the year, a milestone which expects to be a "major value inflection point". The first of two studies of MED2005 got underway in October treating 1,000 men at 60 centres across Europe. Headline data should be released towards the back-end of 2019, the company said."
j777j
10/4/2019
09:28
It's incompetence, barder background is insurance, he has no experience exploiting technology, if the board was credible it would have replaced him but they are his appointees.
slicethepie
10/4/2019
09:26
Futura Medical plc James Barder, Chief Executive mail to: james.barder@futuramedical.com
lbo
Chat Pages: Latest  669  668  667  666  665  664  663  662  661  660  659  658  Older
Your Recent History
LSE
FUM
Futura Med..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20191205 21:56:46